Patent · US Active

5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine

US7638541B2 · kind B2 · utility

33Cited by

4References

2Claims

0Family size

Assignee

Metabolex, Inc. · US

Inventors

Xin Chen · Lexington, US
Peng Cheng · Tianjin, CN
L. Edward Clemens · Davis, US
Jeffrey D. Johnson · Moraga, US
Jingyuan Ma · Sunnyvale, US
Alison Murphy · Milpitas, US
Imad Nashashibi · San Jose, US
Christoper J. Rabbat · San Jose, US
Jiangao Song · Cupertino, US
Maria E. Wilson · San Francisco, US
Yan Zhu · Beijing, CN
Zuchun Zhao · El Sobrante, US

Key dates

Filing date	Dec 26, 2007
Grant date	Dec 29, 2009
Priority date	—
Expiry date	Dec 26, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compounds, compositions, and methods relating to 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine or a pharmaceutically acceptable salt thereof are provided for the treatment of Type II diabetes and other diseases associated with poor glycemic control.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.